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Abstract
We have recently demonstrated that the rheumatoid arthritis
(RA) shared epitope (SE) acts as a ligand that triggers nitric
oxide (NO) signaling in opposite cells. Given the known pro-
oxidative effect of NO and the proposed role of oxidative stress
in the pathogenesis of RA, this study explores whether SE-
triggered signaling can increase cellular oxidative stress. cAMP
levels, adenylyl cyclase activity, and protein kinase A activity
were measured using commercial kits. Generation of reactive
oxygen species (ROS) was quantified using the fluorochrome
dichlorofluorescein diacetate. Oxidative DNA damage was
quantified using the single-cell electrophoresis technique. Here,
we report that cells exposed to cell surface SE-positive HLA-DR
(human leukocyte antigen-DR) molecules, to cell-free
recombinant proteins genetically engineered to express the SE
motif, or to SE-positive synthetic peptide showed diminished
cAMP-dependent signaling, increased ROS levels, and higher
vulnerability to oxidative DNA damage. Introduction of single
amino acid substitutions into SE-positive peptides revealed a
consensus five-amino acid sequence motif of Q/R-K/R-X-X-A
that is necessary and sufficient for SE-triggered signaling. The
pro-oxidative effect of the SE could be reversed by inhibiting NO
production. We conclude that the SE acts as a signaling ligand
that activates an NO-mediated pro-oxidative pathway. The
potential contribution of this signaling aberration to RA
pathogenesis is discussed.
Introduction
The vast majority of patients with rheumatoid arthritis (RA)
carry human leukocyte antigen-DRB1 (HLA-DRB1) alleles
encoding QKRAA, QRRAA, or RRRAA amino acid sequences
in positions 70 to 74 of the DR-β chain, a motif commonly
known as the RA 'shared epitope' (SE) [1]. Immunogenetic
analyses have identified the SE as the main genetic risk factor
in diverse ethnic groups [2] and have documented a particu-
larly strong association with a severe form of the disease [3].
It has also been suggested that a gene-dose effect may exist
in which patients carrying two SE-positive alleles are afflicted
with more severe disease than patients with one SE allele or
none [4].
Despite the major role of genetic factors in RA susceptibility,
the concordance of this disease in monozygotic twins is only
15% [5]. It has therefore been hypothesized that whereas RA
susceptibility is determined genetically, disease onset may
depend on stochastic non-genetic or epigenetic events.
Indeed, increased incidence of stochastically occurring events
such as protein and lipid damage, accelerated telomere short-
ening, DNA damage, and somatic mutations have been
observed in RA patients [6-8] and in non-RA patients carrying
the SE [9]. It is noteworthy that a common denominator for
these events is their association with – or inducibility by – oxi-
dative stress, which has long been implicated in RA [10-15].
Thus, a conceivable unifying explanation is that the SE
2CA = 2-chloroadenosine; AC = adenylyl cyclase; CLIP = class II-associated invariant chain peptide; DCFH-DA = 2',7'-dichlorodihydrofluorescein; 
DMEM = Dulbecco's modified Eagle's medium; DTT = dithiothreitol; EBV = Epstein-Barr virus; EDTA = ethylenediaminetetraacetic acid; HBc = hep-
atitis B core; HLA-DRB1 = human leukocyte antigen-DRB1; HV3 = the third allelic hypervariable region; IC50 = half inhibitory concentration; MHC = 
major histocompatibility complex; NO = nitric oxide; NOS = nitric oxide synthase; PBS = phosphate-buffered saline; PKA = protein kinase A; RA = 
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increases susceptibility to RA by conducing to a pro-oxidative
milieu, which increases the risk of deleterious stochastic
events. Consistent with this model, a gene-environment inter-
action between the SE and smoking, a well-known pro-oxidant
stressor [16], has been recently reported [17], with relative
risks for RA of 7.5 in SE-positive smokers, 2.4 in smokers who
were SE-negative, and 2.8 in SE-positive individuals without a
history of smoking. That study also demonstrated a gene-dose
effect, with a relative risk of 15.7 in smokers carrying two cop-
ies of the SE [17].
In this study, we investigated whether the SE plays a role in
oxidative stress regulation. In prior studies [18,19], we identi-
fied two counteracting pathways that regulate cell sensitivity
to oxidative challenges: an anti-oxidative pathway, which is
triggered by extracellular adenosine and is mediated by cAMP-
dependent protein kinase A (PKA), and a pro-oxidative, nitric
oxide (NO)-mediated pathway that counteracts the cAMP-
mediated pathway, thereby rendering cells more vulnerable to
oxidative damage [18]. More recently, we demonstrated that
the SE acts as a ligand that activates NO signaling in opposite
cells in an allele-specific manner [20]. Here, we report that SE-
triggered NO signaling blocks the cAMP-mediated anti-oxida-
tive pathway and leads to increased vulnerability to oxidative
damage. The SE effect is critically dependent on amino acids
Q/R70, K/R71, and A74 of the DR-β chain, the very same res-
idues previously shown to correlate best with RA susceptibility
in population studies [21].
Materials and methods
Cells, HLA-DR typing, and culture conditions
B-lymphocyte lines prepared from peripheral blood by
Epstein-Barr virus (EBV) transformation were grown in supple-
mented RPMI-1640 medium. B-cell lines were HLA-DR-typed
using commercial, polymerase chain reaction-based, low-
medium-resolution, DRB1 typing kits (Dynal Biotech, now part
of Invitrogen Corporation, Carlsbad, CA, USA) followed by
high-resolution, DRB1 allele-specific typing when indicated. A
total of 40 donors were studied. Thirty-two of them carried one
or two of the following SE-positive HLA-DRB1 alleles: *0101,
*0401, *0404, *0405, or *1001. Eight cell lines carrying the
DRB1 alleles *0301, *07, *08, *13, *15, or *11 composed the
SE-negative group. SE-positive and SE-negative B-cell lines
displayed equivalent levels of HLA-DR surface expression, as
determined by flow cytometry analysis on 10 randomly
selected lines (Additional file 1). The murine L-cell transfect-
ants expressing human HLA-DR-α/β heterodimers were gen-
erated as described [22] and maintained in Dulbecco's
modified Eagle's medium (DMEM) supplemented with 10 mM
HEPES, 2 mM glutamine, 1% penicillin/streptomycin, 10%
fetal calf serum, and 500 μg/ml G418. All L-cell transfectants
displayed equivalent levels of HLA-DR surface expression, as
determined by flow cytometry analysis (Additional file 1).
Human M1 fibroblasts were grown in DMEM containing 10%
fetal bovine serum, penicillin/streptomycin, and 10 mM
HEPES buffer solution.
Synthesis and solid-phase immobilization of peptides
Peptides were synthesized at the University of Michigan Pro-
tein Structure Facility on a Rainin PTI Symphony automated
peptide synthesizer (Protein Technologies, Inc. Tucson AZ,
USA). Each residue was coupled twice with 200 mM HOBt +
HBTU and 400 mM N-methylmorpholine for 60 minutes and
capped with 50% acetic anhydride in dimethylformamide. The
resins used were Fmoc-PAL-PEG resins from Applied Biosys-
tems (Foster City, CA, USA). Peptides were purified to more
than 90% by high-performance liquid chromatography. All
peptides were C- and N-terminally blocked. The sequences of
the peptides used in this study and the DRB1 alleles that cor-
respond to them are shown in Table 1.
To immobilize peptides on a solid phase, cyanogen bromide-
activated Sepharose 4B beads were washed with 1 mM HCl
and incubated with peptides in 0.1 M NaHCO3 and 0.5 M
NaCl (pH 8.0) buffer overnight at 4°C. Five milligrams of pep-
tide was mixed with 1 ml of Sepharose 4B beads. Free Sepha-
rose groups were blocked with 0.2 M glycine (pH 8.0) for 2
hours at room temperature. Columns were washed at 4°C with
the following buffers: 0.1 M NaHCO3, 0.5 M NaCl (pH 8.0)
buffer, 0.5 M CH3COONa (pH 4.0) buffer, and finally phos-
phate-buffered saline (PBS) at pH 7.5. The efficiency of bind-
ing was determined by quantification of the residual
concentration of peptides in the buffer after overnight incuba-
tion with the beads.
SE-expressing recombinant proteins
HLA-DR tetramers DRB1*0401/DRA1*0101 (designated
here as T-DRB1*0401) and DRB1*1501/DRA1*0101 (T-
DRB1*1501) containing class II-associated invariant chain
peptide (CLIP) in the antigenic groove were generated by the
National Institutes of Health Tetramer Facility as previously
described [23]. Chimeric hepatitis B core (HBc) particles
expressing DR-β HV3 (the third allelic hypervariable region)
were prepared as previously described [20].
Membrane preparation
To prepare membranes, 5 × 105 cells were washed in cold
PBS and resuspended in 300 μl of 10 mM Tris-HCl lysis buffer
(pH 7.5) containing 3 mM dithiothreitol (DTT), 400 μM DGTA
(diacylglycerylhydroxymethyltrimethyl-beta-alanine), 2 mM
MgCI2, 0.1 mg/ml PMSF (phenylmethylsulfonyl fluoride), and 1
μg/ml each pepstatin and leupeptine. Cells were homoge-
nized using a glass Dounce Tissue Grinder (Wheaton Science
Products, Millville, NJ, USA). The homogenates were centri-
fuged at 1,000 g for 10 minutes at 4°C. The supernatants
were then centrifuged at 12,000 g for 30 minutes. The result-
ing particulate fractions were suspended in 20 mM Tris-HCl
buffer (pH 7.5) containing 60 mM KCl and 1 mM ethylenedi-Available online http://arthritis-research.com/content/9/1/R5
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aminetetraacetic acid (EDTA). Protein concentration was
determined by the Lowry method.
Measurement of cAMP
Experiments were performed in a serum-free RPMI-1640
medium containing 1% Nutridoma HU (Boehringer Mannheim,
now part of Roche Diagnostics, Basel, Switzerland), 10 mM
HEPES, 200 mM glutamine, and 1% penicillin/streptomycin.
Cells were stimulated with 25 μM forskolin for the indicated
time. The stimulation was stopped by adding one volume of
10% trichloroacetic acid, followed by sonication. The lysates
were centrifuged at 12,000 g for 15 minutes at 4°C, and the
supernatants were extracted three times with five volumes of
diethyl ether. The residual ether was removed by heating the
samples to 70°C for 15 minutes. A kit from Cayman Chemical
Company (Ann Arbor, MI, USA) was used to measure cAMP.
Measurement of PKA activity
By means of a commercial kit (Gibco-BRL, now part of Invitro-
gen Corporation, Carlsbad, CA, USA), PKA activity was quan-
tified based on the transfer of phosphate-32 from γ-P32 ATP to
the synthetic heptapeptide Leu-Arg-Arg-Ala-Ser-Leu-Gly.
Results are expressed as the percentage of activity relative to
maximal activity by a positive control provided with the kit.
Adenylyl cyclase activity assay
Cell membranes were prepared as described above. The com-
position of the reaction buffer was 50 mM triethanolamine (pH
7.4), 1 mM EDTA, 1 mM DTT, 5 mM MgCI2, 5 mM creatine
phosphate, 20 mM rolipram, 1 mM IBMX (3-isobutyl-1-methyl-
xanthine), 1 mM ATP, 0.05 mM guanosine triphosphate, 60 U/
ml creatine phosphate kinase, 4 units per milliliter each of
myokinase and adenosine deaminase type VIII (Sigma-Aldrich,
St. Louis, MO, USA), 60 mM KCl, and 0.2% bovine serum
albumin. The reaction was initiated by the sequential addition
of the cell membrane suspension (10 μg of proteins) to the
incubation medium. The total reaction volume was 70 μl. Incu-
bations were performed for 5 minutes at 32°C. To stop the
reaction, 2 μl of 0.5 M EDTA (pH 8.0) was added, followed by
boiling for 10 minutes. cAMP generation in the reaction, rep-
Table 1
Peptides used in this study
Designation Amino acid sequence Encoded by HLA-DRB1 alleles
65–79*0401 KDLLEQKRAAVDTYC *0401, *0413, *0416, *0421, *1419, *1421
65–79*0402 KDILEDERAAVDTYC *0402, *0414, *0103, *1102, *1116, *1120, *1121, *1301, *1302, *1304, *1308, *1315, *1315, 
*1317, *1319, *1322, *1416
65–79*0403 KDLLEQRRAEVDTYC *0403, *0406, *0407, *0417, *0420
65–79*0404 KDLLEQRRAAVDTYC *0404, *0405, *0408, *0410, *0419, *0101, *0102, *1402, *1406, *1409, *1413, *1417, *1420
65–79*1001 KDLLERRRAAVDTYC *1001
Pentapeptide
1Q K R A A *0401, *0413, *0416, *0421, *1419, *1421
2Q R R A A *0404, *0405, *0408, *0410, *0419, *0101, *0102, *1402, *1406, *1409, *1413, *1417, *1420
3D E R A A *0402, *0414, *0103, *1102, *1116, *1120, *1121, *1301, *1302, *1304, *1308, *1315, *1315, 
*1317, *1319, *1322, *1416
4 RRRAA *1001
5 RRRAE *09, *1401, *1404, *1405, *1407, *1408, *1410, *1411, *1414, *1418
6D R R A A *1601, *1602, *1605, *0415, *11011, *11012, *11041, *11042, *1105, *1106, *11081, 
*11082*1109, *1110, *1112, *1115, *1118, *1119, *1122, *1201, *12021, *12022, *12031, *12032, 
*1305, *1306, *1307, *1311, *1312, *1314, *1321, *0805
7 QARAA *15, *1309
8Q K R G R *03, *0422, *1107
9 QKRLA Not applicable (modified peptide)
10 QKRAE Not applicable (modified peptide)
11 QKCLA Not applicable (modified peptide)
12 QECLA Not applicable (modified peptide)
13 DKCLA Not applicable (modified peptide)
A, alanine; C, cysteine; D, aspartic acid; E, glutamic acid; G, glycine; HLA-DRB1, human leukocyte antigen-DRB1; I, isoleucine; K, lysine; L, 
leucine; Q, glutamine; R, arginine; T, threonine; V, valine; Y, tyrosine.Arthritis Research & Therapy    Vol 9 No 1    Ling et al.
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resenting adenylyl cyclase (AC) activity, was determined using
a cAMP assay kit (Amersham, now part of GE Healthcare, Lit-
tle Chalfont, Buckinghamshire, UK).
Measurement of reactive oxygen species levels
To measure spontaneous reactive oxygen species (ROS) pro-
duction by B lymphocytes, cells were first loaded with 10 μM
2',7'-dichlorodihydrofluorescein (DCFH-DA) for 30 minutes,
washed, and plated at a density of 1 × 105 per well in round-
bottom 96-well plates (OptiPlate™ 96F; PerkinElmer Life And
Analytical Sciences, Inc., Waltham, MA, USA) in 100 μl of
DMEM-phenol red-free medium. Fluorescence level was
recorded continuously over a period of 200 minutes by a
Fusion™ αHT system (PerkinElmer Life And Analytical Sci-
ences, Inc.) at an excitation wavelength of 485 nm and an
emission wavelength of 530 nm.
To measure ROS in adherent M1 cells, sub-confluent cultures
were detached from flasks using 0.05% trypsin, and 5 × 103
cells per well were seeded into 96-well plates. After an over-
night culture, cells were washed with DMEM-phenol red-free
medium twice and loaded with DCFH-DA, and dichlorofluo-
rescein (DCF) fluorescence was recorded as above.
Quantification of oxidative DNA damage by the comet 
assay
Sub-confluent fibroblasts were detached from the tissue-cul-
ture flasks with 0.05% trypsin solution. After centrifugation,
cells were washed and re-suspended in serum-free DMEM,
divided into 1.5-ml Eppendorf tubes, and centrifuged at 2,500
rpm for 10 minutes. Ten micromolar 2-chloroadenosine (2CA)
was added and samples were kept in a 37°C incubator for 30
minutes. In some experiments, cells were pre-incubated with
peptides or various inhibitors for the indicated times at 37°C
prior to exposure to 2CA. At the end of incubation, cells were
washed with PBS and treated with 100 μM H2O2 in 0.5 ml of
PBS on ice for 20 minutes. At the end of H2O2 treatment, cells
were immediately microfuged for 15 seconds. The cells were
washed with cold PBS twice and re-suspended at 1 × 105
cells per milliliter in ice-cold PBS. Five microliters of cell sus-
pension was mixed with 50 μl of molten LMAgarose, and the
mixture was placed onto CometSlide™ (Trevigen, Inc., Gaith-
ersburg, MD, USA). Slides were placed at 4°C in the dark for
10 minutes, immersed in pre-chilled lysis solution (Trevigen,
Inc.), and kept at 4°C for an additional 30 minutes. At the end
of incubation, the slides were placed in a 50-ml Coplin jar con-
taining alkali buffer for 30 minutes at room temperature in the
dark and then immersed in 50 ml of Tris borate-EDTA (TBE)
buffer for 5 minutes. Slides were then placed flat onto a gel
tray submerged in TBE buffer in a horizontal electrophoresis
apparatus and were aligned equidistant from the electrodes.
Electrophoresis was performed at 1 V/cm for 10 minutes. At
the end of electrophoresis, samples were fixed in 100% meth-
anol for 5 minutes and 100% ethanol for 5 minutes. After dry-
ing, 50 μl of diluted SYBR Green was added onto each circle
of agarose. Comet tail fluorescence intensity was quantified
with a Diagnostic Instruments (Sterling Heights, MI, USA) dig-
itized camera mounted on a Nikon Eclipse E400 (Nikon USA,
Melville, NY, USA) microscope, using Scion Image software
(Scion Corporation, Frederick, MD, USA). Quantification of
comet fluorescence was performed as previously described
[18]. Each data point was derived from 30 to 100 individual
cells. To mitigate unavoidable inter-experimental variability in
fluorescent units and to allow better comparisons among dif-
ferent experiments, the data are shown as the percentage of
DNA damage protection (the percentage of decrement in tail
fluorescence intensity with 2CA relative to the intensity
recorded in cells treated with H2O2 only) ± standard error of
the mean. As an illustrative example, in medium, M1 cells had
a background of 258,791 ± 27,930 fluorescence units (A).
Exposure of these cells to H2O2 resulted in 1,549,668 ±
163,699 units (B) but in the presence of 2CA was only
885,197 ± 86,147 units (C). The calculated DNA damage
protection by 2CA in medium was therefore 51.47% ± 6.3%
(1 - [(C - A)/(B - A)] × 100). In contrast, in the presence of an
SE-expressing ligand, the corresponding counts were
217,921 ± 25,483 units (A), 1,408,434 ± 179,542 units (B),
and 1,442,636 ± 162,897 units (C), with a calculated DNA
damage protection rate of -2.87% ± 8.89%.
Statistical analysis
Unless stated otherwise, Student's t test was used. Statistical
significance was achieved at a p  value of less than 0.05
(marked with an asterisk). Dose-response curves and calcula-
tion of half inhibitory concentration (IC50) were performed
using PRISM 3.0 software (GraphPad Software, Inc., San
Diego, CA, USA).
Results
We have recently demonstrated that the SE acts as a ligand
capable of triggering NO signaling in opposite cells [20].
Consistent with the known inhibitory effect of NO on the
cAMP-mediated pathway [24,25], cells encountering the SE
displayed impaired cAMP signaling (Figure 1). For example,
EBV-transformed B-cell lines expressing SE-encoding HLA-
DRB1 alleles had a much lower PKA activation in response to
stimulation with the AC-stimulating agent forskolin compared
to SE-negative lines (Figure 1a). To determine whether the sig-
naling aberration was attributable to the DRB1 gene itself or
was a result of another gene secondary to linkage disequilib-
rium, we studied murine L-cell transfectants expressing human
HLA-DR-α/β heterodimers on their surface [22]. As can be
seen in Figure 1b, L cells expressing SE-positive DR-β chains
on their surface through cDNA transfection (lines L565.5 and
L300.8, expressing alleles DRB1*0401  and  DRB1*0404,
respectively) produced significantly less cAMP in response to
forskolin compared to transfectants expressing SE-negative
DR-β chains (lines L514.3 and L259.3, expressing alleles
DRB1*0402 and DRB1*0403, respectively). Activation of the
cAMP-dependent kinase PKA was likewise significantly lowerAvailable online http://arthritis-research.com/content/9/1/R5
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Figure 1
Inhibition of cAMP-dependent signaling by the shared epitope (SE) Inhibition of cAMP-dependent signaling by the shared epitope (SE). (a) Epstein-Barr virus-transformed B-cell lines expressing SE-positive or SE-
negative human leukocyte antigen-DRB1 (HLA-DRB1) alleles were stimulated with the adenylyl cyclase (AC) activator forskolin (25 μM) for 12 min-
utes, and protein kinase A (PKA) activity was determined. The values in parentheses represent the number of donors in each group. (b) L-cell trans-
fectants expressing SE-positive or SE-negative HLA-DRB1 alleles were stimulated with the AC activator forskolin (25 μM) over a time course, and 
cAMP levels were quantified. (c) L-cell transfectants were stimulated with forskolin as in (b), and PKA activity was determined. (d) M1 cells were 
pre-incubated overnight with 50 μg/ml of different soluble 15 mer synthetic peptides corresponding to the HV3 region (residues 65 to 79) encoded 
by SE-positive or SE-negative HLA-DRB1 alleles. Cells were then stimulated with 25 μM forskolin, and cell membrane AC activity was determined. 
(e) Intact M1 cells were pre-incubated overnight with either SE-positive or SE-negative soluble 15 mer peptides, and cAMP levels were determined 
12 minutes after stimulation with forskolin. (f) M1 cells were pre-incubated for 1 hour with different 15 mer peptides immobilized on Sepharose 
beads and then stimulated with 2-chloroadenosine (2CA, 1 μM), and PKA activity was measured over a time course. Black circles indicate SE-posi-
tive peptide 65–79*0401, and white circles indicate SE-negative peptide 65–79*0402. (g) L-cell transfectants expressing SE-positive or SE-nega-
tive HLA-DRB1 alleles were pre-incubated for 15 minutes in the presence or absence of the non-selective nitric oxide synthase inhibitor N-nitro-L-
arginine methyl ester (L-NAME, 4 mM) and then stimulated with forskolin (25 μM), and cAMP levels were measured. NS, not significant.Arthritis Research & Therapy    Vol 9 No 1    Ling et al.
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in SE-expressing transfectants compared to transfectant lines
expressing SE-negative alleles (Figure 1c). We have verified
that the observed findings are not a transfection-associated
artifact in which a seemingly lower cAMP activation in SE-
expressing transfectants is a mere reflection of an enhancing
effect of the SE-negative transfected genes rather than true
inhibition by the SE-positive genes. To address this question,
we compared cAMP signaling between SE-expressing trans-
fectants and untransfected cells or cells transfected with a
vector that does not allow surface expression of the DR mole-
cule (Additional file 2). In both cases, SE-expressing transfect-
ants displayed markedly lower cAMP activation. Thus, the SE
effect was not due to an artifact caused by transfection but
represented a bona fide inhibition of cAMP signaling.
Consistent with our previous data [20], synthetic 15 mer pep-
tides containing SE sequences could mimic the SE effect in its
natural conformation. As can be seen, such peptides inhibited
forskolin-induced AC activation (Figure 1d) and generation of
cAMP (Figure 1e), resulting in inhibition of PKA activation (Fig-
ure 1f). The inhibitory effect of the SE was mediated by NO.
As shown in Figure 1g, L-cell transfectants expressing SE-
positive HLA-DR molecules had impaired cAMP response to
activation by forskolin. However, this impairment was com-
pletely reversed in cells that had been pre-incubated with the
NO synthase (NOS) inhibitor L-NAME (N-nitro-L-arginine)
(Figure 1g). Taken together, these data indicate that the SE
inhibits cAMP-mediated signaling due to its activation of an
antagonistic, NO-mediated pathway.
The cAMP-mediated pathway has been previously shown to
activate an anti-oxidative cellular response, whereas NO has
been found to exert a pro-oxidative effect [18]. Given the dia-
metrically opposite effects of the SE on the cAMP- and the
NO-mediated pathways on the one hand and the proposed
role of oxidative stress in the pathogenesis of RA [10-15] on
the other, we proceeded to examine whether the SE could
affect ROS production. To that end, we first studied spontane-
ous ROS levels in B-lymphocyte lines from 40 HLA-DR-typed
individuals. Cells were loaded with the fluorescent ROS probe
DCFH-DA and were cultured over a time course at high den-
sity to allow close cell-cell contact. As shown in Figure 2, SE-
positive cells demonstrated a robust spontaneous ROS pro-
duction. Curves of two representative cell lines are shown to
illustrate the difference between SE-positive and SE-negative
cells (Figure 2a). It is noteworthy that the ROS curves showed
a biphasic shape with a steeper slope during the first hour. The
reason for this pattern is unknown; however, it could represent
an additional mechanical stress in the early phase, during
which cells are adapting to the high-density culture conditions.
To avoid this potential artifact, we based the calculation of
ROS production rates on the later phase of the curve (80 to
200 minutes). As can be seen in Figure 2b, mean ROS pro-
duction rates were markedly higher in the SE-positive group
compared to the SE-negative group (p = 1.4 × 10-5).
To investigate whether the SE is directly involved, we used
recombinant multimeric HBc molecules engineered to express
HV3 (residues 65 to 79) of different DRB1-encoded DR-β
chains [20]. HBc multimeric proteins are efficient non-replica-
tive and non-infective carriers of foreign epitopes [26]. Impor-
tantly, the tips of each spike form α-helical structures,
mimicking the native conformation of the HV3. Oligonucle-
otides encoding residues 65 to 79 of either the SE-positive
allele DRB1*0401 or the SE-negative allele DRB1*0402 were
inserted at the tips of the HBc spikes as we previously
described [20]. As can be seen in Figure 2c, HLA class II-neg-
ative M1 cells produced much higher ROS levels when incu-
bated with the SE-expressing multimeric protein HBc*0401
compared to cells incubated with the SE-negative control pro-
tein HBc*0402. Similarly, M1 cells incubated with the SE-pos-
itive 15 mer peptide 65–79*0401 produced a much more
robust ROS response compared to cells incubated with the
control 15 mer peptide 65–79*0402 (Figure 2d). Thus, accel-
erated ROS production can be seen in cells upon contact with
other SE-expressing cells or with cell-free SE ligands.
Among its various functions, NO has been found to increase
susceptibility to oxidative DNA damage by counteracting the
genoprotective effect of the adenosine-activated cAMP path-
way [18]. Given our previous findings that the SE can trigger
NO production [20], which in turn inhibits cAMP signaling
(Figure 1), we proceeded to determine whether cells carrying
SE-encoding DRB1 alleles are more susceptible to DNA dam-
age. To that end, adenosine-treated L-cell transfectants were
challenged with H2O2 and the extent of DNA damage was
quantified. As can be seen in Figure 3a, SE-negative transfect-
ants L514.3 and L259.3 mounted adequate adenosine-medi-
ated resistance to H2O2-induced DNA damage, whereas SE-
positive transfectant L565.5 cells failed to respond to adeno-
sine and consequently suffered more extensive DNA damage.
To investigate whether the DR molecule is directly involved,
we used SE-positive and SE-negative HLA-DR tetramers. The
assembly of major histocompatibility complex (MHC) class II
tetrameric molecules depends on the presence of an antigenic
groove peptide that should conform to a sequence motif,
which is distinct for each allele. To allow comparisons
between the SE-negative and SE-positive tetramers inde-
pendent of allele-specific groove peptides, we used tetramers
containing a covalently bound CLIP [23]. As can be seen in
Figure 3b, adenosine-treated M1 fibroblasts stimulated with
the SE-positive T-DRB1*0401 tetramer sustained much more
DNA damage when challenged with H2O2 compared to cells
incubated with the control, SE-negative T-DRB1*1501
tetramer. Because T-DRB1*0401 and T-DRB1*1501 share
identical DR-α chains and groove peptides, their differential
signaling activity can be attributed only to their distinct DR-β
chains. Inhibition of adenosine-mediated resistance to oxida-
tive DNA damage could also be seen in cells incubated with
the SE-expressing multimeric protein HBc*0401 as comparedAvailable online http://arthritis-research.com/content/9/1/R5
Page 7 of 12
(page number not for citation purposes)
to cells incubated with the SE-negative capsids HBc*0402
(Figure 3c).
Pro-oxidative signaling could also be triggered by synthetic
peptides containing the SE sequence (Figure 4). As can be
seen, cells incubated with SE-positive 15 mer peptides 65–
79*0401 or 65–79*0404 prior to treatment with adenosine
and then exposed to H2O2 suffered more oxidative DNA dam-
age. Control peptides derived from the SE-negative alleles
DRB1*0402 (designated 65–79*0402) or DRB1*0403 (des-
ignated 65–79*0403) had no effect (Figure 4a).
Peptides 65–79*0404 and 65–79*0403 differ by a single
amino acid residue (A74 versus E74, respectively) (Table 1).
This maps the active region to the SE itself (residues 70 to
74). To ascertain this possibility, we synthesized 5 mer pep-
tides corresponding to the SE (QKRAA, QRRAA, and
RRRAA, representing alleles DRB1*0401, DRB1*0404, and
DRB1*1001, respectively). As can be seen in Figure 4b, 5 mer
peptides QKRAA, QRRAA, and RRRAA all had a pro-oxidative
effect, whereas 5 mer peptides expressing non-SE sequences
(for example, RRRAE, DRRAA, QKRGR, or DERAA) had no
such effect. To determine which of the five SE amino acid res-
idues are critical, we introduced single amino acid substitu-
tions into the 5 mer peptide QKRAA. We found that Q/R70,
K/R71, and A74 are critical amino acids for the SE effect,
whereas residues 72 and 73 do not seem to play a role (Figure
4b). Thus, a consensus motif Q/R-K/R-X-X-A was identified as
necessary and sufficient for SE signaling. Synthetic peptides
showed effectiveness at nanomolar concentrations. The IC50
values of their pro-oxidative effects were 250 nM for peptide
65–79*0401, 29 nM for peptide QKRAA, and 40 nM for
QRRAA (Figure 4c).
Finally, the involvement of NO in SE-triggered pro-oxidative
signaling was investigated. As can be seen in Figure 5a, pre-
incubation of M1 cells with the NOS inhibitor L-NMMA (L-NG-
monomethyl arginine citrate) prevented the pro-oxidative
Figure 2
The shared epitope (SE) accelerates endogenous reactive oxygen species (ROS) production The shared epitope (SE) accelerates endogenous reactive oxygen species (ROS) production. (a) Time-course ROS levels in representative SE-pos-
itive (red line) and SE-negative (blue line) B-lymphocyte cell lines. (b) ROS production rates in B lymphocytes. Results are shown as the mean ± 
standard error of the mean fluorescent units per minute (FU/minute) during the linear late phase of the ROS curve (80 to 200 minutes). Data of the 
SE-positive (SE+) and SE-negative (SE-) groups were compiled from three to five consecutive experiments in each cell line. The values in parenthe-
ses represent the number of donors in each group. (c) ROS levels in M1 cells stimulated with 2.5 μg/ml of either SE-positive hepatitis B core (HBc) 
capsids (HBc*0401, red line) or SE-negative HBc capsids (HBc*0402, blue line). (d) ROS levels in M1 cells stimulated with 100 μg/ml of either an 
SE-positive 15 mer peptide (65–79*0401, red circles) or an SE-negative 15 mer peptide (65–79*0402, blue circles). Calculations of p values in (c) 
and (d) were based on paired t test analysis. DCF, dichlorofluorescein.Arthritis Research & Therapy    Vol 9 No 1    Ling et al.
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effect of SE-expressing peptide 65–79*0401. The NOS1-
selective inhibitor TRIM (trifluoromethylphenylimidazole), but
not the potent NOS2-selective inhibitor 1400 W, reversed the
SE-triggered pro-oxidative effect (Figure 5b,c). The PKG
(cGMP-dependent kinase) inhibitor KT5823 reversed SE-trig-
gered pro-oxidative effects, implicating this kinase as a likely
downstream signaling molecule in the SE-triggered pro-oxida-
tive pathway.
Discussion
We report herein that the SE acts as an allele-specific ligand
that inhibits an adenosine-mediated anti-oxidative pathway in
opposite cells, thereby increasing cell vulnerability to oxidative
damage. Both adenosine and the cAMP-mediated pathway
have been previously shown to attenuate oxidative stresses
[27-36]. Adenosine is a known anti-inflammatory and cytopro-
tective molecule secreted by injured cells in order to protect
the bystander tissue [37,38]. For example, in cardiomyocytes,
adenosine-mediated signaling has been found to attenuate
oxidative stress during reoxygenation [34], and in mesangial
cells, adenosine has been shown to inhibit phorbol myristate
acetate-induced intracellular production of ROS [35]. We
have recently demonstrated that activation of the cAMP
pathway by extracellular adenosine via adenosine receptors of
the A2 type protects cells against oxidative DNA damage.
Increased NO levels, on the other hand, inhibit the protective
effect of cAMP, thereby rendering cells more vulnerable to oxi-
dative damage [18]. Thus, a balance between two pathways,
mediated respectively by NO and cAMP, determines the
extent of oxidative damage in cells.
Here, we demonstrate that the SE, when expressed in its
native conformation on the cell surface, inhibits cAMP-
dependent signaling. Synthetic peptides (15 mer) corre-
sponding to the HV3 region of SE-positive HLA-DR molecules
likewise inhibit the pathway in HLA class-II negative cells. By
using NOS inhibitors, we further demonstrate that the effect of
SE on cAMP-mediated signaling is due to its action as a ligand
capable of activating NO-mediated signaling in opposite cells
[20].
The molecular targets affected by the SE-triggered NO path-
way are unknown. In other systems, NO has been shown to
inhibit cAMP signaling either through a direct effect on AC or
indirectly via activation of soluble guanylyl cyclase, resulting in
cGMP-mediated activation of phosphodiesterases [24,25].
Inhibition of Gs  protein-coupled receptor activation is yet
another potential mechanism [39]. The adenosine receptor,
however, is a less likely target in the system described here,
given the SE-inhibited activation by forskolin, which is a post-
receptor event. Thus, the SE inhibitory effect is likely targeted
at the AC level or further downstream.
Our experiments using isozyme-selective NOS inhibitors sug-
gest that the mechanism of NO increase by SE involves acti-
Figure 3
The shared epitope (SE) attenuates adenosine-induced protection  against oxidative DNA damage The shared epitope (SE) attenuates adenosine-induced protection 
against oxidative DNA damage. (a) The potency of adenosine-mediated 
anti-oxidative signaling was determined in L-cell transfectants express-
ing cDNA corresponding to DRB1*0401 (L565.5), DRB1*0402 
(L514.3), or DRB1*0403 (L259.3). (b) Human M1 fibroblasts were 
incubated for 1 hour with or without 24 μg/ml of SE-positive (T-
DRB1*0401) or SE-negative (T-DRB1*0401) tetrameric molecules. At 
the end of incubation, the extent of adenosine-induced protection 
against oxidative DNA damage was determined as above. (c) M1 
human fibroblasts were pre-incubated overnight in the absence or pres-
ence of 2.5 μg/ml of either HBc*0401 or HBc*0402 multimeric pro-
teins. At the end of incubation, the extent of adenosine-induced 
protection against oxidative DNA damage was determined. *p < 0.05.Available online http://arthritis-research.com/content/9/1/R5
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vation of NOS1 (Figure 5) [20]. It should be cautioned,
however, that the fidelity of chemical NOS inhibitors is imper-
fect. Additionally, the studies reported here involved fibrob-
lasts. Whether a different NOS isozyme may mediate SE
signaling in other cell types is unknown. Further studies using
more specific inhibition techniques (for example, RNA interfer-
ence) will be required to conclusively identify the NOS iso-
zymes involved in different lineages.
We demonstrate here that, as a result of SE-triggered NO pro-
duction, extracellular adenosine fails to activate the cAMP-
mediated anti-oxidative pathway. Our results (Figure 2) further
indicate that cells encountering the SE produce more ROS in
the absence of any exogenously added oxidative challenge.
Thus, the SE impairs the ability of cells to effectively use the
cAMP-mediated anti-oxidative response. Because ROS medi-
ate important intracellular signaling events [10,11], it is con-
ceivable that SE-associated accumulation of ROS could have
functional cell activation consequences. At excessive levels,
ROS can also cause oxidative damage to macromolecules. It
is noteworthy, therefore, that the extent of baseline DNA dam-
age in unchallenged cells was not different in the presence or
absence of the SE (data not shown). However, when exposed
to exogenous oxidative challenges (that is, addition of H2O2),
SE-encountering cells sustained more DNA damage than cells
that had not encountered that ligand. Thus, these in vitro
results suggest that, although the SE does not cause sponta-
neous oxidative damage, it could increase the risk of such
damage during exogenous oxidative challenges. The in vivo
implications of these findings are unknown, but it is tempting
to speculate that in the absence of exogenous oxidative stress,
individuals carrying SE-positive HLA-DRB1 alleles may expe-
rience only minor signaling aberrations resulting from the
known immunomodulatory effects of ROS [10,11]. However,
Figure 4
Pro-oxidative signaling by shared epitope (SE)-expressing peptides Pro-oxidative signaling by shared epitope (SE)-expressing peptides. (a,b) The potency of adenosine-induced anti-oxidative signaling was determined 
in human M1 fibroblasts, which had been pre-incubated overnight with 50 μg/ml of different 15 mer (a) or 5 mer (b) peptides. *p < 0.05. (c) Dose-
response analysis of soluble peptide-mediated pro-oxidative effect. AA, amino acid; IC50, half inhibitory concentration.Arthritis Research & Therapy    Vol 9 No 1    Ling et al.
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when challenged with exogenous oxidative stresses, these
individuals may be at a higher risk of oxidative damage to
macromolecules.
By using synthetic peptides corresponding to the HV3 region
encoded by different DRB1 alleles (Figures 1 and 4), we dem-
onstrate that the three known SE sequences (that is, QKRAA,
QRRAA, and RRRAA) can all trigger pro-oxidative signals. We
further demonstrate that an amino acid sequence motif of Q/
R-K/R-X-X-A is necessary and sufficient for activation of the
SE-triggered pathway. It is intriguing that the very same motif
has been previously shown to correlate best with RA suscep-
tibility in RA population studies [21].
We propose that these findings could provide new insights
into some unresolved questions about the role of the SE in RA.
The prevailing hypotheses to explain the association of SE and
RA are based on the known role of HLA-DR molecules in anti-
gen presentation. However, published data to support
presentation of a specific antigen as a primary event in RA are
equivocal. Moreover, the SE effect is not exclusive to RA; sev-
eral other human diseases, as well as several animal models,
have also been shown to be associated with SE-expressing
HLA-DRB1 alleles [40-44]. One example of the enigmatic role
of the SE is illustrated by transgenic mice expressing the SE-
positive allele DRB1*0401. These mice have been found to
develop a more severe experimental encephalomyelitis [45], a
disease model that is induced by immunization against nerv-
ous system-derived antigens, which have little to do with arthri-
tis. Thus, the SE demonstrates promiscuous association with
pathogenically diverse diseases but with no apparent antigen-
or species-specificity. It is therefore conceivable that, in addi-
tion to its role in the adaptive immune system, the SE pos-
sesses antigen-non-specific functions by activation of the
innate immune system.
This study describes a novel innate immunity function of the
SE: activation of a pro-oxidative NO-mediated signaling cas-
Figure 5
Mapping the shared epitope (SE)-triggered pro-oxidative signaling pathway Mapping the shared epitope (SE)-triggered pro-oxidative signaling pathway. (a) M1 cells were pre-incubated for 20 minutes with the nitric oxide syn-
thase (NOS) inhibitor L-NMMA (500 μM) and exposed to Sepharose bead-immobilized allele-specific 15 mer peptides for 1 hour, and the extent of 
adenosine-induced protection against oxidative DNA damage was determined. (b) M1 cells were incubated with or without 50 μg/ml of peptide 65–
79*0401 or 65–79*0404 in the presence or absence of NOS1 inhibitor TRIM (trifluoromethylphenylimidazole) (250 μM) or the NOS2-selective 
inhibitor 1400 W (0.2 μM). After overnight incubation, cells were washed, stimulated with 2-chloroadenosine, followed by oxidative challenge with 
H2O2, and the extent of DNA damage was quantified. The concentration of each inhibitor was adjusted to 10-fold higher than its IC50. *p <0.02; **p 
<10-5. (c) Dose-response curve of TRIM effect. Cells were incubated overnight with 50 μg/ml of peptide 65–79*0404 in the presence of different 
concentrations of TRIM. At the end of incubation, cells were collected and adenosine-induced protection against DNA damage was quantified as 
above. (d) M1 cells were pre-incubated for 10 minutes with the PKG inhibitor KT5823 (1 μM) and subsequently exposed to Sepharose bead-immo-
bilized peptide 65–79*0401. The extent of adenosine-induced protection against oxidative DNA damage was determined. IC50, half inhibitory con-
centration; L-NMMA, L-NG-monomethyl arginine citrate; PKG, cGMP-dependent kinase.Available online http://arthritis-research.com/content/9/1/R5
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cade. The pathway is activated within 1 hour after exposure to
soluble peptides but can be triggered within minutes after
stimulation with solid phase-immobilized peptides, suggesting
that cross-linking of a cell surface receptor may be involved.
The identity of the receptor is under study.
ROS and NO have been previously implicated as important
players in the immune aberrations observed in RA. For exam-
ple, increased ROS levels have been directly blamed for T-cell
hyporesponsiveness [10,11], and NO-mediated resistance to
Fas-induced apoptosis has been described in RA [14]. The
data reported here offer a testable hypothesis regarding the
role of SE in RA pathogenesis. Moreover, due to increased
surface expression of class II MHC molecules in inflammatory
sites, SE-triggered pro-oxidative effects offer a plausible expla-
nation for the self-perpetuating nature of the disease. In addi-
tion, the cumulative effect of intercurrent exogenous oxidative
challenges throughout life could conceivably render patients
with RA more vulnerable to mutations [7,8] and premature tel-
omeric loss [9].
Conclusion
We demonstrate here that the SE acts as an allele-specific lig-
and that activates an NO-mediated pro-oxidative signaling in
opposite cells. Based on the proposed role of oxidative stress
in RA pathogenesis, it is tempting to speculate that the signal-
ing effect reported here may contribute to disease susceptibil-
ity and/or severity in RA.
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